Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
102 hedge funds and large institutions have $1.2B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 15 closing their positions.
478% more call options, than puts
Call options by funds: $18.4M | Put options by funds: $3.19M
68% more capital invested
Capital invested by funds: $714M → $1.2B (+$488M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
2% more funds holding
Funds holding: 100 → 102 (+2)
1.76% more ownership
Funds ownership: 76.44% → 78.19% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$31.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.8M |
| 3 |
JP Morgan Chase
New York
|
+$16.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$17.5M |
| 2 |
DM
Deerfield Management
New York
|
-$14.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.37M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.83M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$4.18M |
BHVN Hedge Fund Activity: Q2 2018 in Review
102 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2018, worth a combined $1.2B — up 68% from $714M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new BHVN positions and 15 closed out — a net gain of 2 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was State Street, adding an estimated $31.2M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $17.5M sold.
- 102 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2018, up from 100 in Q1 2018.
- Funds reported $1.2B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2018, up 68% quarter-over-quarter.
- 17 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2018 and 15 closed out, a net change of +2 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2018 was State Street, an estimated $31.2M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2018 was Ghost Tree Capital, an estimated $17.5M sold.
Based on aggregated 13F filings for Q2 2018.